Sangamo Therapeutics (SGMOQ) Capital Leases (2016 - 2018)

Sangamo Therapeutics' Capital Leases history runs 3 years deep, the most recent figure standing at $27.7 million for Q4 2018.

• On a quarterly basis, Capital Leases rose 11.93% year-over-year to $27.7 million in Q4 2018; TTM through Dec 2018 was $27.7 million, a 11.93% increase from a year earlier, with the FY2018 full-year figure at $27.7 million, up 11.93% from the prior year.
• Capital Leases grew to $27.7 million in Q4 2018 per SGMOQ's latest filing, from $26.9 million in the prior quarter.
• Across five years, Capital Leases topped out at $27.7 million in Q4 2018 and bottomed at $213000.0 in Q1 2016.
• The 3-year median for Capital Leases is $3.9 million (2016), against an average of $12.4 million.
• Across the five-year window, Capital Leases surged 1744.13% in 2017 and advanced 11.93% in 2018, its largest moves.
• Year by year, Capital Leases stood at $3.9 million in 2016, then surged by 527.07% to $24.7 million in 2017, then advanced by 11.93% to $27.7 million in 2018.
• Per Business Quant, the three latest SGMOQ Capital Leases figures stand at $27.7 million (Q4 2018), $26.9 million (Q3 2018), and $26.2 million (Q2 2018).